21/11/2025 - Research

A new cellular model reveals which mutations drive progression to myelodysplastic syndrome and leukemia in patients with GATA2 deficiency

A research team has created the first humanised cellular model to study GATA2 deficiency, a rare genetic disorder that predisposes individuals to severe blood conditions such as myelodysplastic syndrome and leukaemia. The study shows that, although the initial GATA2 mutation weakens haematopoietic stem cells, it is additional mutations -particularly in the SETBP1 gene- that drive disease progression. 

17/11/2025 - Projects, Research

Micropores pave the way for infection research

A new study provides a powerful way to study infections in environments that closely mimic human organs. The strategy, tested in a bone-marrow-on-chip model, was developed by researchers from ISGlobal, IGTP, I3S at Porto University, and IN2UB, as part of the HIDDENVIVAX project, funded by "la Caixa" Foundation.

04/11/2025 - Research

Study identifies that the sequence of previous diseases may help predict the risk of long COVID

Provides a new perspective: what matters is not only which previous diseases a person has, but also the order in which they appeared and how they interact. This approach makes it possible to identify risk profiles for long COVID that had not been detected until now. The research was conducted within the framework of the COVICAT study, coordinated in collaboration with ISGlobal.

30/10/2025 - Campus Can Ruti, Projects, Research

Precision increases in a project led by Germans Trias using AI to detect early facial changes in patients with acromegaly

A project led by the Germans Trias i Pujol University Hospital and Research Institute has developed an AI-based facial recognition system, AcroFace, capable of detecting early signs of acromegaly with 93% accuracy. The researchers are now conducting a larger pilot study with 4,000 images from the general population to confirm these promising results and improve early diagnosis of this rare disease.

22/10/2025 - Campus Can Ruti, Research

Tears could open a new avenue for diagnosing and monitoring eye and neurodegenerative diseases

Researchers from the IGTP and HUGTiP have reviewed the current knowledge on the use of tear-derived extracellular vesicles as a source of biomarkers for both ocular and neurodegenerative diseases. They highlight the advantages of this approach compared with more invasive methods and discuss the remaining challenges for its clinical application.

16/10/2025 - Innovation, Research, Success Stories

HIPRA receives European Commission approval for the commercialisation of its COVID-19 vaccine adapted to the LP.8.1 variant

The demonstration of the vaccine's efficacy in its preclinical phase was carried out at the Comparative Medicine and Bioimage Centre of Catalonia, a trategic project of IGTP.

14/10/2025 - Campus Can Ruti, Research

RUTI® vaccine improves treatment of non-invasive bladder cancer by boosting immune response and providing clinical benefits

A clinical trial involving 40 patients, led by IrsiCaixa and IGTP and conducted at HUGTiP, confirms that the RUTI® vaccine, owned by Archivel Farma, enhances the effectiveness of the current treatment for non-muscle-invasive bladder cancer.

13/10/2025 - Projects, Research

A vascular mechanism may explain the persistence of COVID-19 symptoms and their greater impact, especially in women

A study led by GCAT-IGTP links the VEGFA protein to long COVID, especially in postmenopausal women, suggesting a vascular mechanism behind persistent symptoms. The findings highlight the need to consider sex and hormonal status in long COVID research and treatment.

02/10/2025 - Projects, Research

SEXPROM study launched to address sexual health of people living with HIV through a gender-based approach

CEEISCAT and the Grupo de Trabajo sobre Tratamientos del VIH (gTt-VIH) announce the start of data collection for the SEXPROM Study, a pioneering investigation in Spain that will explore sexual satisfaction among people living with HIV, with a differentiated focus by gender and sexual orientation.

30/09/2025 - Campus Can Ruti, Research, Success Stories

An international study opens the door to a new standard treatment for head and neck cancer

The combination of the drug nivolumab with chemotherapy improves survival in patients with high-risk head and neck cancer and could become the new standard treatment, according to the results of an international trial led by professionals from ICO, IGTP and IDIBELL.